Alvotech Welcomes Stelara Biosimilar Into Phase III Development
Joins Alvotech’s Biosimilar Humira Candidate
Alvotech has announced two studies running in parallel for the firm’s AVT04 ustekinumab biosimilar referencing Janssen’s $7.7bn Stelara treatment for autoimmune diseases, including a Phase III comparative study.
You may also be interested in...
Teva discussed its proposed rivals in the US biosimilar adalimumab space, biosimilar business development plans and prioritizing debt during its Q3 earnings call. The Israeli firm’s revenues succumbed to challenges in the US generics space.
Japan’s Meiji Seika Pharma and Korea’s Dong-A have struck an exclusive licensing deal with Intas for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.
Samsung Bioepis has become the latest firm to move an ustekinumab biosimilar into Phase III trials, with the firm’s SB17 proposed Stelara rival kicking off a study in plaque psoriasis patients.